Alturas Minerals Corp

Altimmune's inclusion in Nasdaq Biotechnology Index (NBI) led to a 3.54% stock rise. The company, trading at $8.18/share with a $581.8M market cap, has a strong Altman Z-score of 17.01 but a low Piotroski F-Score. Pemvidutide, a GLP-1 obesity treatment, shows promise but faces revenue and DSO challenges.

Altimmune, Inc. announced its addition to the Nasdaq Biotechnology Index, effective December 23, 2024. The company, focused on developing pemvidutide for obesity and MASH, anticipates significant progress in 2025.

Altimmune (Nasdaq: ALT) added to Nasdaq Biotechnology Index (NBI) effective December 23, 2024. CEO Vipin K. Garg highlights this as recognition following major progress. Anticipating significant milestones in 2025, including topline data from Phase 2b IMPACT trial of pemvidutide in MASH expected in Q2.

The Emulate Liver-Chip S1 replicates human liver sinusoid biology, offering 87% sensitivity and 100% specificity in detecting drug-induced liver injury (DILI), outperforming traditional models. It enables early toxicity detection, aligns with regulatory expectations, and can save over $3 billion annually by reducing drug development failures. The Liver-Chip R1 enhances capabilities for diverse drug classes, advancing drug safety and reducing reliance on animal testing.

DelveInsight's report on Nonalcoholic Steatohepatitis (NASH) provides insights into historical and forecasted epidemiology, market trends, current treatment practices, emerging drugs, and market size from 2019 to 2032 in the United States, EU5, and Japan. Key companies and therapies in the NASH market are highlighted, including recent developments like Aligos Therapeutics' Phase 1 data presentation.

Gilead Sciences announced 81% of PBC participants achieved durable biochemical response by Month 30 with Livdelzi, and 41% normalized ALP levels. Livdelzi also reduced pruritus severity, resolving itch in 27% of participants.

LEGEND study results show lanifibranor significantly lowers HbA1c in MASH and T2D patients, with 50% achieving HbA1c <6.5% at week 24. Combination with empagliflozin improves outcomes and avoids weight gain.

B.Riley Financial's Mayank Mamtani reiterates Buy rating on Altimmune (ALT) with $20.00 target, citing successful FDA End of Phase 2 meeting for pemvidutide, paving way for Phase III obesity program. UBS also initiated coverage with a Buy rating and $26.00 target.

The ATTENTION trial in Korea and Taiwan showed Vemlidy (tenofovir alafenamide) significantly reduced liver-related events in non-cirrhotic hepatitis B patients with normal ALT levels, emphasizing early treatment's importance to prevent HCC and reduce healthcare costs.